Adriana Weinberg1, Sharon Huang2, Anna-Barbara Moscicki3, Afred Saah4, Myron J Levin5. 1. Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine, and Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado. 2. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts. 3. Department of Pediatrics, University of California Los Angeles, Los Angeles, California. 4. Merck & Co., North Wales, Pennsylvania. 5. Section of Pediatric Infectious Diseases, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Abstract
OBJECTIVE: To determine the magnitude and persistence of quadrivalent human papillomavirus (HPV)16 and HPV18 B-cell and T-cell memory after three or four doses of quadrivalent HPV vaccine (QHPV) in HIV-infected children. METHODS: Seventy-four HIV-infected children immunized with four doses and 23 with three doses of QHPV had HPV16 and HPV18 IgG B-cell and IFNγ and IL2 T-cell ELISPOT performed at 2, 3.5 and 4-5 years after the last dose. RESULTS: HPV16 and HPV18 T-cell responses were similar in both treatment groups, with higher responses to HPV16 vs. HPV18. These HPV T-cell responses correlated with HIV disease characteristics at the study visits. Global T-cell function declined over time as measured by nonspecific mitogenic stimulation. B-cell memory was similar across treatment groups and HPV genotypes. There was a decline in HPV-specific B-cell memory over time that reached statistical significance for HPV16 in the four-dose group. CONCLUSION: B-cell and T-cell memory did not significantly differ after either three or four doses of QHPV in HIV-infected children. The clinical consequences of decreasing global T-cell function and HPV B-cell memory over time in HIV-infected children requires further investigation.
OBJECTIVE: To determine the magnitude and persistence of quadrivalent human papillomavirus (HPV)16 and HPV18 B-cell and T-cell memory after three or four doses of quadrivalent HPV vaccine (QHPV) in HIV-infectedchildren. METHODS: Seventy-four HIV-infectedchildren immunized with four doses and 23 with three doses of QHPV had HPV16 and HPV18 IgG B-cell and IFNγ and IL2 T-cell ELISPOT performed at 2, 3.5 and 4-5 years after the last dose. RESULTS:HPV16 and HPV18 T-cell responses were similar in both treatment groups, with higher responses to HPV16 vs. HPV18. These HPV T-cell responses correlated with HIV disease characteristics at the study visits. Global T-cell function declined over time as measured by nonspecific mitogenic stimulation. B-cell memory was similar across treatment groups and HPV genotypes. There was a decline in HPV-specific B-cell memory over time that reached statistical significance for HPV16 in the four-dose group. CONCLUSION: B-cell and T-cell memory did not significantly differ after either three or four doses of QHPV in HIV-infectedchildren. The clinical consequences of decreasing global T-cell function and HPV B-cell memory over time in HIV-infectedchildren requires further investigation.
Authors: Mari Nygård; Alfred Saah; Christian Munk; Laufey Tryggvadottir; Espen Enerly; Maria Hortlund; Lara G Sigurdardottir; Scott Vuocolo; Susanne K Kjaer; Joakim Dillner Journal: Clin Vaccine Immunol Date: 2015-06-17
Authors: Myron J Levin; Anna-Barbara Moscicki; Lin-Ye Song; Terrence Fenton; William A Meyer; Jennifer S Read; Edward L Handelsman; Barbara Nowak; Carlos A Sattler; Alfred Saah; David R Radley; Mark T Esser; Adriana Weinberg Journal: J Acquir Immune Defic Syndr Date: 2010-10 Impact factor: 3.731
Authors: Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; J Michael Berry; Naomi Jay; David Aboulafia; David L Cohn; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky Journal: J Infect Dis Date: 2010-10-15 Impact factor: 5.226
Authors: Kinga K Smolen; Laura Gelinas; Lisa Franzen; Simon Dobson; Meena Dawar; Gina Ogilvie; Mel Krajden; Edgardo S Fortuno; Tobias R Kollmann Journal: Vaccine Date: 2012-03-31 Impact factor: 3.641
Authors: Howard Minkoff; Ye Zhong; Robert D Burk; Joel M Palefsky; Xiaonan Xue; D Heather Watts; Alexandra M Levine; Rodney L Wright; Christine Colie; Gypsyamber D'Souza; L Stewart Massad; Howard D Strickler Journal: J Infect Dis Date: 2010-03 Impact factor: 5.226
Authors: Elizabeth Crowe; Nirmala Pandeya; Julia M L Brotherton; Annette J Dobson; Stephen Kisely; Stephen B Lambert; David C Whiteman Journal: BMJ Date: 2014-03-04
Authors: Gad Murenzi; Fabienne Shumbusho; Natasha Hansen; Athanase Munyaneza; Julia C Gage; Benjamin Muhoza; Faustin Kanyabwisha; Amanda Pierz; Patrick Tuyisenge; Kathryn Anastos; Philip E Castle Journal: BMJ Open Date: 2022-08-25 Impact factor: 3.006
Authors: Lisa Staadegaard; Minttu M Rönn; Nirali Soni; Meghan E Bellerose; Paul Bloem; Marc Brisson; Mathieu Maheu-Giroux; Ruanne V Barnabas; Melanie Drolet; Philippe Mayaud; Shona Dalal; Marie-Claude Boily Journal: EClinicalMedicine Date: 2022-08-03